BRPI0912988A2 - compostos bicíclicos tendo atividade no receptor cxcr4. - Google Patents

compostos bicíclicos tendo atividade no receptor cxcr4.

Info

Publication number
BRPI0912988A2
BRPI0912988A2 BRPI0912988A BRPI0912988A BRPI0912988A2 BR PI0912988 A2 BRPI0912988 A2 BR PI0912988A2 BR PI0912988 A BRPI0912988 A BR PI0912988A BR PI0912988 A BRPI0912988 A BR PI0912988A BR PI0912988 A2 BRPI0912988 A2 BR PI0912988A2
Authority
BR
Brazil
Prior art keywords
receptor activity
bicyclic compounds
cxcr4 receptor
cxcr4
bicyclic
Prior art date
Application number
BRPI0912988A
Other languages
English (en)
Inventor
A Rodrigues Gerard
E Donello John
E Garst Michael
L Beard Richard
Vu Thong
T Duong Tient
Vuligonda Vidyasagar
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0912988A2 publication Critical patent/BRPI0912988A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0912988A 2008-05-22 2009-05-18 compostos bicíclicos tendo atividade no receptor cxcr4. BRPI0912988A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5524808P 2008-05-22 2008-05-22
PCT/US2009/044347 WO2009143058A1 (en) 2008-05-22 2009-05-18 Bicyclic compounds having activity at the cxcr4 receptor

Publications (1)

Publication Number Publication Date
BRPI0912988A2 true BRPI0912988A2 (pt) 2019-09-24

Family

ID=41059527

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912988A BRPI0912988A2 (pt) 2008-05-22 2009-05-18 compostos bicíclicos tendo atividade no receptor cxcr4.

Country Status (11)

Country Link
US (1) US8193203B2 (pt)
EP (1) EP2300456A1 (pt)
JP (1) JP2011523420A (pt)
KR (1) KR20110018380A (pt)
CN (1) CN102105463A (pt)
AU (1) AU2009249246A1 (pt)
BR (1) BRPI0912988A2 (pt)
CA (1) CA2725066A1 (pt)
IL (1) IL209318A0 (pt)
RU (1) RU2010152290A (pt)
WO (1) WO2009143058A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153310A1 (en) * 2010-06-02 2011-12-08 Trius Therapeutics Dihydrofolate reductase inhibitors
WO2013019966A1 (en) * 2011-08-04 2013-02-07 Allergan, Inc. Aromatic bycyclic derivatives as cxcr4 receptor modulators
AU2013237226A1 (en) 2012-03-19 2014-10-09 Emory University Quinazoline compounds and their use in therapy
WO2014105958A2 (en) 2012-12-26 2014-07-03 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
MA41169A (fr) * 2014-12-17 2017-10-24 Acraf Composés antibactériens à large spectre d'activité
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
HUE061989T2 (hu) 2016-03-16 2023-09-28 Kura Oncology Inc Szubsztituált tieno[2,3-D]pirimidin származékok mint menin-MLL inhibitorai és alkalmazási eljárások
WO2017161002A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-mll and methods of use
JP2020514388A (ja) 2017-03-24 2020-05-21 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
EP3645006A4 (en) * 2017-06-30 2020-12-16 The University of North Carolina at Chapel Hill HETEROCROMATIN GENE REPRESSION INHIBITORS
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
CN110669036B (zh) * 2018-07-02 2022-02-11 盛世泰科生物医药技术(苏州)有限公司 一类具有cxcr4信号通路抑制活性的杂环化合物及其应用
CN115160294B (zh) * 2022-06-27 2023-09-29 中山大学 一种G9a/GLP共价抑制剂及其制备方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074105A1 (en) 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
WO2006105056A2 (en) * 2005-03-28 2006-10-05 Fmc Corporation Insecticidal 2,4-diaminoquinazolines and related derivatives
FR2891829A1 (fr) 2005-10-12 2007-04-13 Sanofi Aventis Sa Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique
KR20080089416A (ko) * 2005-12-21 2008-10-06 페인셉터 파마 코포레이션 개폐 이온 통로를 조절하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
KR20110018380A (ko) 2011-02-23
IL209318A0 (en) 2011-01-31
WO2009143058A1 (en) 2009-11-26
US8193203B2 (en) 2012-06-05
EP2300456A1 (en) 2011-03-30
JP2011523420A (ja) 2011-08-11
CN102105463A (zh) 2011-06-22
AU2009249246A1 (en) 2009-11-26
CA2725066A1 (en) 2009-11-26
US20090312305A1 (en) 2009-12-17
RU2010152290A (ru) 2012-06-27

Similar Documents

Publication Publication Date Title
BRPI0912988A2 (pt) compostos bicíclicos tendo atividade no receptor cxcr4.
NL1028624A1 (nl) Alfa-aryl- of -heteroarylmethyl-bèta-piperidinopropaan-zuurverbindingen als ORL1-receptorantagonisten.
BRPI0817111A2 (pt) Estrutura de suporte de corpo
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0722004A2 (pt) Posto de saúde.
BRPI0907364A2 (pt) Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
BRPI0920889A2 (pt) macrociclos peptidomiméticos.
DK2344691T3 (da) Strikket sengelagen
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
BRPI0813245A2 (pt) Escova de dentes.
IT1390737B1 (it) Macchina per la realizzazione di articoli assorbenti.
DE602007008831D1 (de) Cyclohexyl-sulfonamid-derivate mit h3-rezeptoraktivität
BRPI0907108A2 (pt) escova de dentes.
BRPI0815797A2 (pt) Compostos 8-azabiciclo[3.2.1]octil-2-hidroxibanzamida como antagonistas de receptor opióide mu
BRPI0815668A2 (pt) compostos pirrol tendo atividade biológica antagonista e agonista de receptor de esfingosina-1-fosfato.
BRPI0720078A2 (pt) 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a)
BRPI0913449A2 (pt) plataforma de suporte.
BRPI0820633A2 (pt) antagonistas de receptores de il-4 muteína modificada
AP2010005512A0 (en) Novel compounds active as muscarinic receptor antagonists.
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
BRPI1008680A2 (pt) pé de suporte.
BR112012014495A2 (pt) cosmético de autonivelamento.
DK2257534T3 (da) 3-aminoalkyl-1,4-diazepan-2-on-melanocortin-5-receptorantagonister
IL185640A0 (en) Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
BRPI0912193A2 (pt) compostos terapêuticos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.